SPONTAN Shows Positive Outcomes in Younger Men with ED
Filed with ASX · · 3 pages · English
LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that a small, independent observational case series has reported positive real-world use of its intranasal erectile dysfunction product, SPONTAN®, in men experiencing situational erectile difficulties associated with sexual performance anxiety. The observations involved five physically healthy men aged 20–30 years
Earlier from LTR Pharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patients Dosed in SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
- Ethics Approval Received for SPONTAN Phase II Clinical Study
- LTR increases LevOmega stake to 43% with $1m investment
Later from LTR Pharma
- Appendix 4D and Half Yearly Report
- SPONTAN Phase II Clinical Study Completes Recruitment
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- LTR Secures First U.S. Commercial Agreement for ROXUS
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma